Thi Nhat Ho An, Shmelev Artem, Joshi Astha, Ho Nghi
MedStar Harbor Hospital, Baltimore, MD, USA.
Saint Agnes Hospital, Baltimore, MD, USA.
J Hematol. 2019 Mar;8(1):11-16. doi: 10.14740/jh475. Epub 2019 Mar 30.
Sickle cell disease (SCD) affects 100,000 patients in the USA. However, no recent data was available for annual national trends in hospitalization rates, in-hospital mortality, hospital length of stay (LOS) and costs of SCD admissions due to its complications.
This study was conducted to study the trends of hospitalization rates, in-hospital mortality, LOS and hospital charges due to SCD-related complications in African American (AA) patients from 2004 to 2012 in the USA. Complications included acute chest syndrome, splenic sequestration, bacterial pneumonia, sepsis, stroke, deep vein thrombosis (DVT) or pulmonary embolism, retinal circulation complications, priapism, disorders related to biliary stones, or those required blood transfusions. We obtained the study population from the Nationwide Inpatient Sample.
Hospital admission rate rose steadily from 106 per 100,000 AA population in 2004 to 137 in 2012. Seasonal and trend decomposition revealed the highest hospitalization rate in January. Hospital LOS decreased from 7.1 ± 7.65 days in 2004 to 6.23 ± 6.42 days in 2012. Hospital charges increased from 15.35 (8.99 - 27.57) thousand dollars per admission in 2004 to 24.78 (14.37 - 45.24) in 2012. Medicaid remained the primary payer in the highest number of patients in 9 years. In-hospital mortality did not change significantly, being 1.03% in 2004 and 1.02% in 2012, with no significant seasonal variation in mortality. Most common complications were acute pain crisis and blood transfusion requirement. Biliary pathology was the only complication that decreased over time. Admissions for each complication were initially uprising with a decline from 2010 to 2012, except for DVT/pulmonary embolism with a significant uptrend.
Overall, from 2004 to 2012, hospital admission rates and charges increased, and hospital LOS decreased, while in-hospital mortality remained unchanged.
在美国,镰状细胞病(SCD)影响着10万名患者。然而,由于其并发症导致的SCD住院率、院内死亡率、住院时间(LOS)和住院费用的年度全国趋势,目前尚无最新数据。
本研究旨在研究2004年至2012年美国非裔(AA)患者因SCD相关并发症导致的住院率、院内死亡率、住院时间和住院费用的趋势。并发症包括急性胸综合征、脾隔离症、细菌性肺炎、败血症、中风、深静脉血栓形成(DVT)或肺栓塞、视网膜循环并发症、阴茎异常勃起、与胆结石相关的疾病或需要输血的疾病。我们从全国住院患者样本中获取了研究人群。
住院率从2004年每10万AA人群中的106例稳步上升至2012年的137例。季节性和趋势分解显示1月份住院率最高。住院时间从2004年的7.1±7.65天降至2012年的6.23±6.42天。住院费用从2004年每次住院15.35(8.99 - 27.57)千美元增加到2012年的24.78(14.37 - 45.24)千美元。在9年中,医疗补助仍然是支付患者数量最多的主要支付方。院内死亡率没有显著变化,2004年为1.03%,2012年为1.02%,死亡率没有显著的季节性变化。最常见的并发症是急性疼痛危机和输血需求。胆道病变是唯一随时间减少的并发症。除DVT/肺栓塞呈显著上升趋势外,每种并发症的入院人数最初呈上升趋势,从2010年到2012年有所下降。
总体而言,从2004年到2012年,住院率和费用增加,住院时间缩短,而院内死亡率保持不变。